Evaluation of combination gene therapy with PTEN and antisense hTERT for malignant glioma in vitro and xenografts

Cellular and Molecular Life Sciences

Volumn 64, Issue 5, 2007, Pages 621-631

  You, Yongping ^a   Geng, Xiaozeng ^a   Zhao, Peng ^a   Fu, Zhen ^a   Wang, Cunzu ^a   Chao, Shengwu ^a   Liu, Ning ^a   Lu, Ailing ^a   Gardner, Kevin ^b   Pu, Peiyu ^c   Kong, Chunsheng ^c   Ge, Yun ^b   Judge, Susan I V ^d,e   Li, Qingdi Q ^b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NATIONAL CANCER INSTITUTE   (United States)

^c TIANJIN MEDICAL UNIVERSITY   (China)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Antisense hTERT; Combination therapy; Gene therapy; Glioma; PTEN; Xenograft

Indexed keywords

ADENOVIRUS VECTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TELOMERASE REVERSE TRANSCRIPTASE; COMPLEMENTARY DNA; TELOMERASE; TERT PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFICACY; DRUG MECHANISM; DRUG SYNTHESIS; ENZYME ACTIVITY; GENE THERAPY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REVIEW; WILD TYPE; XENOGRAFT; ANIMAL; APOPTOSIS; ARTICLE; BRAIN TUMOR; CELL CYCLE; CELL DIVISION; CELL SURVIVAL; GENETICS; GLIOMA; METHODOLOGY; MOUSE MUTANT; PATHOLOGY; TUMOR CELL LINE;

ADENOVIRIDAE;

ANIMALS; APOPTOSIS; BRAIN NEOPLASMS; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; DNA, ANTISENSE; GENE THERAPY; GLIOMA; HUMANS; MICE; MICE, SCID; PTEN PHOSPHOHYDROLASE; TELOMERASE; TRANSPLANTATION, HETEROLOGOUS;

EID: 34247880410     PISSN: 1420682X     EISSN: 15691632     Source Type: Journal    
DOI: 10.1007/s00018-007-6424-4     Document Type: Review

References (48)

1. Gurney, J. G. and Kadan-Lottick, N. (2001) Brain and other central nervous system tumors: rates, trends, and epidemiology. Curr. Opin. Oncol. 13, 160-166.
2. You, Y., Pu, P., Peng, Q., Xia, Z., Huang, Q., Wang, C. and Wang, G. (2004) Telomerase activity and regulation in meningiomas. Chin. J. Neurosurg. 21, 89-91.
3. Kim, N. M., Piatysrek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L., Coviello, G. M., Wright, W. E., Weinrich, S. L. and Shay, J. W. (1994) Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011-2015.
4. Shay, J. W. and Bacchetti, S. (1997) A survey of telomerase activity in human cancer. Eur. J. cancer 33, 787-791.
5. Meyerson, M., Counter, C. M., Eaton, E. N., Ellisen, L. W., Steiner, P., Dickinson, C. S., Ziaugra, L., Beijershergen, R. L., Davidoff, M. J., Liu, Q., Bacchetti, S., Haber, D. A. and Weinberg, R.A. (1997) hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 90, 785-795.
6. Takakura, M., Kyo, S., Kanaya, T., Tanaka, M. and Inoue, M. (1998) Expression of human telomerase subunits and correlation with telomerase activity in cervical cancer. Cancer Res. 58, 1558-1561.
7. Widschwendter, A., Muller, H. M., Hubalek, M. M., Wiedemair, A., Fiegl, H., Goebel, G. and Mueller-Holzner, E. (2004) Methylation status and expression of human telomerase reverse transcriptase in ovarian and cervical cancer. Gynecol. Oncol. 93, 407-416.
8. Tabori, U., Ma, J., Carter, M., Zielenska, M., Rutka, J., Bouffet, E., Bartels, U., Malkin, D. and Hawkins, C. (2006) Human telomere reverse transcriptase expression predicts progression and survival in pediatric intracranial ependymoma. J. Clin. Oncol. 24, 1522-1528.
9. Boldrini, L., Pistolesi, S., Gisfredi, S., Ursino, S., Lupi, G., Caniglia, M., Pingitore, R., Basolo, F., Parenti, G. and Fontanini, G. (2003) Telomerase in intracranial meningiomas. Int. J. Mol. Med. 12, 943-947.
10. Krams, M., Hero, B., Berthold, F., Parwaresch, R., Harms, D. and Rudolph,. P. (2003) Full-length telomerase reverse transcriptase messenger RNA is an independent prognostic factor in neuroblastoma. Am. J. Pathol. 162, 1019-1026.
11. Yannopoulos, A., Dimitriadis, E., Scorilas, A., Trangas, T., Markakis, E. and Talieri, M. (2005) mRNA quantification and clinical evaluation of telomerase reverse transcriptase subunit (hTERT) in intracranial tumours of patients in the island of Crete. Br. J. Cancer 93, 152-158.
12. Bae-Jump, V. L., Zhou, C. X., Gehrig, P. A., Whang, Y. E. and Boggess, J. F. (2006) Rapamycin inhibits hTERT telomerase mRNA expression, independent of cell cycle arrest. Gynecol. Oncol. 100, 487-494.
13. Kraemer, K., Fuessel, S., Schmidt, U., Kotzsch, M., Schwenzer, B., Wirth, M. P. and Meye, A. (2003) Antisense-mediated hTERT inhibition specifically reduces the growth of human bladder cancer cells. Clin. Cancer Res. 9, 3794-3800.
14. Natarajan, S., Chen, Z., Wancewicz, E. V., Monia, B. P. and Corey, D.R. (2004) Telomerase reverse transcriptase (hTERT) mRNA and telomerase RNA (hTR) as targets for downregulation of telomerase activity. Oligonucleotides 14, 263-273.
15. Pallini, R., Sorrentino, A., Pierconti, F., Maggiano, N., Faggi, R., Montano, N., Maira, G., Larocca, L. M., Levi, A. and Falchetti, M. L. (2006) Telomerase inhibition by stable RNA interference impairs tumor growth and angiogenesis in glioblastoma xenografts. Int. J. Cancer 118, 2158-2167.
16. Fan, X., Aalto, Y., Sanko, S. G., Knuutila, S., Klatzmann, D. and Castresana, J. S. (2002) Genetic profile, PTEN mutation and therapeutic role of PTEN in glioblastomas. Int. J. Oncol. 21, 1141-1150.
17. Li, L., Liu, F. H., Salmonsen, R. A., Turner, T. K., Litofsky, N. S., Cristofano, A. D., Pandolfi, P. P., Jones, S. N., Recht, L. D. and Ross, A. H. (2002) PTEN in neural precursor cells: Regulation of migration, apoptosis, and proliferation. Mol. Cell. Neurosci. 20, 21-29.
18. Edwards, L. A., Thiessen, B., Dragowska, W. H., Daynard, T., Bally, M. B. and Dedhar, S. (2005) Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth. Oncogene 24, 3596-3605.
19. Korshunov, A., Sycheva, R., Golanov, A. (2005) The prognostic relevance of molecular alterations in glioblastomas for patients age < 50 years. Cancer 104, 825-832.
20. Grill, J., van Beusechem, V. W., van Der Valk, P., Dirven, C. M., Leonhart, A., Pherai, D. S., Haisma, H. J., Pinedo, H. M., Curiel, D. T. and Gerritsen, W.R. (2001) Combined targeting of adenoviruses to integrins and epidermal growth factor receptors increases gene transfer into primary glioma cells and spheroids. Clin. Cancer Res. 7, 641-650.
21. Lu, W., Zhou, X., Hong, B., Liu, J. and Yue, Z. (2004) Suppression of invasion in human U87 glioma cells by adenovirus-mediated co-transfer of TIMP-2 and PTEN gene. Cancer Lett. 214, 205-213.
22. Lee, J. S., Lee, J.H., Poo, H., Kim, M. S., Lee, S.H., Sung, M.H. and Kim, C. J. (2006) Growth inhibitory effect of triple antitumor gene transfer using Semliki Forest virus vector in glioblastoma cells. Int. J. Oncol. 28, 649-654.
23. You, Y. P., Pu, P. Y., Peng, Q., Xia, Z. B., Huang, Q., Wang, C. Y. and Wang, G. X. (2002)Telomerase activity and regulation in human neuroepithelial tumors. Chin. J. Surg. 40, 90-93.
24. Wang, H., Pu, P. Y., Li, J., Wang, C. Y., Dong, L., Jian, D. R., Kang, C. S. and Wang, G. X. (2003) The expression of PTEN, FAK and Ki67 in human gliomas. Chin. J. Nerv. Ment. Dis. 29, 418-420.
25. He, T. C., Zhou, S. B., da Costa, L. T., Yu, J., Kinzler, K.W. and Vogelstein, B. (1998) A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. USA 95, 2509-2514.
26. Hahnfeldt, P., Panigrahy, D., Folkman, J. and Hlatky, L. (1999) Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res. 59, 4770-4775.
27. Kim, N. M. and Wu, F. (1997) Advances in quantification and characterization of telomerase activity by the telomeric repeat amplification protocol (TRAP). Nucleic Acids Res. 25, 2595-2597.
28. Yokoyama, Y., Takahashi, Y., Shinohara, A., Wan, X., Takahashi, S., Niwa, K. and Tamaya, T. (2000) The 5′-end of hTERT mRNA is a good target for hammerhead ribozyme to suppress telomerase activity. Biochem. Biophys. Res. Commun. 273, 316-321.
29. Fu, X. H., Zhang, J. S., Zhang, N. and Zhang, Y. D. (2005) Combination of telomerase antisense oligonucleotides simultaneously targeting hTR and hTERT produces synergism of inhibition of telomerase activity and growth in human colon cancer cell line. World J. Gastroenterol. 11, 785-790.
30. Takakura, M., Kyo, S., Kanaya, T., Hirano, H., Takeda, J., Yutsudo, M. and Inoue, M. (1999) Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res. 59, 551-557.
31. Kyo, S. and Inoue, M. (2002) Complex regulatory mechanisms of telomerase activity in normal and cancer cells: how can we apply them for cancer therapy. Oncogene 21, 688-697.
32. Zhou, C. X., Bae-Jump, V. L., Whang, Y. E., Gehrig, P. A. and Boggess, J. F. (2006) The PTEN tumor suppressor inhibits telomerase activity in endometrial cancer cells by decreasing hTERT mRNA levels. Gynecol. Oncol. 101, 305-310.
33. Kang, S. S., Kwon, T., Kwon, D. Y., and Do, S. I. (1999) Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit. J. Biol. Chem. 274, 13085-13090.
34. Asano, T., Yao, Y., Zhu, J., Li, D., Abbruzzese, J. L., and Reddy, S. A. (2004) The PI3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-κB and c-Myc in pancreatic cancer cells. Oncogene 23, 8571-8580.
35. Moon, S. K., Kim, H.M., and Kim, C. H. (2004) PTEN induces G1 cell cycle arrest and inhibits MMP-9 expression via the regulation of NF-κB and AP-1 in vascular smooth muscle cells. Arch. Biochem. Biophys. 421, 267-276.
36. Li, Y.M., Zhou, B. P., Deng, J., Pan, Y., Hay, N., and Hung, M. C. A. (2005) Hypoxia-independent hypoxia-inducible factor-1 activation pathway induced by phosphatidylinositol-3 kinase/ Akt in HER2 overexpressing cells. Cancer Res. 65, 3257-3263.
37. Chung, T. W., Lee, Y. C., and Kim, C. H. (2004) Hepatitis B viral HBx induces matrix metalloproteinase-9 gene expression through activation of ERK and PI-3K/AKT pathways: involvement of invasive potential. FASEB. J. 18, 1123-1125.
38. Nishi, H., Kyo, S., Shay, J. W., and Isaka, K. (2004) Hypoxia-inducible factor 1 mediates upregulation of telomerase (hTERT). Mol. Cell. Biol. 24, 6076-6083.
39. Yatabe, N., Kyo, S., Isaka, K., Inoue, M. (2004) HIF-1-mediated activation of telomerase in cervical cancer cells. Oncogene 23, 3708-3715.
40. Wetterau, L. A., Francis, M. J., Ma L., and Cohen, P. (2003) Insulin-like growth factor I stimulates telomerase activity in prostate cancer cells. J. Clin. Endocrinol. Metab. 88, 3354-3359.
41. Zhou, C., Gehrig, P.A., Whang, Y. E., and Boggess, J. F. (2003) Rapamycin inhibits telomerase activity by decreasing the hTERT mRNA level in endometrial cancer cells. Mol. Cancer Ther. 2, 789-795.
42. Jiang, F., Bao, J., Li, P., Nicosia, S. V., and Bai, W. (2004) Induction of ovarian cancer cell apoptosis by 1,25-dihydroxyvitamin D3 through the down-regulation of telomerase. J. Biol. Chem. 279, 53213-53221.
43. Ikeda, N., Uemura, H., Ishiguro, H., Hori, M., Hosaka, M., Kyo, S., Miyamoto, K., Takeda, E., and Kubota, Y. (2003) Combination treatment with 1α,25-dihydroxyvitamin D3 and 9-cis-retinoic acid directly inhibits human telomerase reverse transcriptase transcription in prostate cancer cells. Mol. Cancer Ther. 2, 739-746.
44. Davies, M. A., Lu, Y., Sano, T., Fang, X., Tang, P., LaPushin, R., Koul, D., Bookstein, R., Stokoe, D., Yung, W. K. A., Mills, G. B. and Steck, P. (1998) Adenoviral transgene expression of MMAC1/PTEN in human glioma cells inhibits Akt activation and induces anoikis. Cancer Res. 58, 5285-5290.
45. Furnari, F. B., Huang, H. J. and Cavenee, W. K. (1998) The phosphoinsitol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells. Cancer Res. 58, 5002-5008.
46. Cheney, I. W., Johnson, D. E., Vaillancourt, M. T., Vanzini, J., Morimoto, A., Demers, G. W., Wills, K. N., Shabram, P. W., Bolen, J. B., Tavtigian, S. V. and Bookstein, R. (1998) Suppression of tumorigenicity of glioblastoma cells by advenovirus-mediated MMAC1/PTEN gene transfer. Cancer Res. 58, 2331-2334.
47. Ghosh, S. S., Gopinath, P., and Ramesh, A. (2006) Adenoviral vectors - A promising tool for gene therapy. Appl. Biochem. Biotechnol. 133, 9-29.
48. Bangari, D. S., and Mitta,l S. K. (2006) Current strategies and future directions for eluding adenoviral vector immunity. Curr. Gene Ther. 6, 215-226.